GlaxoSmithKline R&D chief Hal Barron touted a fresh set of updated data on their anti-BCMA antibody drug conjugate GSK2857916 on Thursday, pointing to a solid 60% response rate from their DREAMM-1 study on multiple myeloma as he burnished the pharma giant's improved late-stage prospects in oncology.Image: Hal Barron. GSK
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,900+ biopharma pros who read Endpoints News by email every day.Free Subscription